OBJECTIVE: The study's objective was to estimate human papillomavirus (HPV) genotype-specific seroprevalence to determine population HPV exposure and inform vaccine policy. METHODS: This study is a cross-sectional prevalence survey of 878 women of Pueblorrico, a rural town of Colombia. A standardized questionnaire was used to obtain information on demographic characteristics, sexual and reproductive history, and smoking habits. Seropositivity to HPV-16, -18, -31, and -58 was determined by virus-like particles in an enzyme-linked immunosorbent assay. RESULTS: Overall seropositivity to any HPV genotype was 27.9%. The combined seroprevalence of women 15 to 19 and 20 to 24 years old was 35.4% (95% confidence interval [CI], 25.9-46.2) and 36.0% (95% CI, 27.7-45.3), respectively. Seroprevalence for HPV-16 was 17% (95% CI, 14.6-19.6); for HPV-18, 9.8% (95% CI, 8.0-11.9); for HPV-31, 11.4% (95% CI, 9.5-13.7); and for HPV 58, 12.5% (95% CI, 10.5-14.9). Higher HPV seropositivity was associated with the lifetime number of occasional sexual partners (odds ratio, 3.05; 95% CI, 1.26-7.37) and having more than 2 regular sexual partners (odds ratio, 3.00; 95% CI, 1.21-7.45) in women younger than 44 and older than 45 years old, respectively. Use of oral contraceptives and tobacco/cigarettes was significantly associated with reduced HPV seropositivity in women older than 45 but not in women younger than 44 years old. CONCLUSIONS: Human papillomavirus seropositivity is associated with measures of sexual behavior, particularly a greater lifetime number of sexual partners. Hormonal and tobacco/cigarette use may be factors influencing the HPV seropositivity in women older than 45 years old.
OBJECTIVE: The study's objective was to estimate human papillomavirus (HPV) genotype-specific seroprevalence to determine population HPV exposure and inform vaccine policy. METHODS: This study is a cross-sectional prevalence survey of 878 women of Pueblorrico, a rural town of Colombia. A standardized questionnaire was used to obtain information on demographic characteristics, sexual and reproductive history, and smoking habits. Seropositivity to HPV-16, -18, -31, and -58 was determined by virus-like particles in an enzyme-linked immunosorbent assay. RESULTS: Overall seropositivity to any HPV genotype was 27.9%. The combined seroprevalence of women 15 to 19 and 20 to 24 years old was 35.4% (95% confidence interval [CI], 25.9-46.2) and 36.0% (95% CI, 27.7-45.3), respectively. Seroprevalence for HPV-16 was 17% (95% CI, 14.6-19.6); for HPV-18, 9.8% (95% CI, 8.0-11.9); for HPV-31, 11.4% (95% CI, 9.5-13.7); and for HPV 58, 12.5% (95% CI, 10.5-14.9). Higher HPV seropositivity was associated with the lifetime number of occasional sexual partners (odds ratio, 3.05; 95% CI, 1.26-7.37) and having more than 2 regular sexual partners (odds ratio, 3.00; 95% CI, 1.21-7.45) in women younger than 44 and older than 45 years old, respectively. Use of oral contraceptives and tobacco/cigarettes was significantly associated with reduced HPV seropositivity in women older than 45 but not in women younger than 44 years old. CONCLUSIONS:Human papillomavirus seropositivity is associated with measures of sexual behavior, particularly a greater lifetime number of sexual partners. Hormonal and tobacco/cigarette use may be factors influencing the HPV seropositivity in women older than 45 years old.
Authors: Patricia Sadate-Ngatchou; Joseph J Carter; Stephen E Hawes; Qinghua Feng; Taylor Lasof; Joshua E Stern; Tsung-Chieh Jane Fu; Denise A Galloway; Laura A Koutsky; Rachel L Winer Journal: Sex Transm Dis Date: 2016-03 Impact factor: 2.830
Authors: Rachel A Katzenellenbogen; Joseph J Carter; Joshua E Stern; Melinda S Butsch Kovacic; Parinda A Mehta; Sharon L Sauter; Denise A Galloway; Rachel L Winer Journal: Clin Vaccine Immunol Date: 2015-02-04
Authors: Lauren E Wilson; Michael Pawlita; Phillip E Castle; Tim Waterboer; Vikrant Sahasrabuddhe; Patti E Gravitt; Mark Schiffman; Nicolas Wentzensen Journal: Int J Cancer Date: 2013-05-29 Impact factor: 7.396
Authors: Darron R Brown; Xavier Castellsagué; Daron Ferris; Suzanne M Garland; Warner Huh; Marc Steben; Cosette M Wheeler; Alfred Saah; Alain Luxembourg; Se Li; Christine Velicer Journal: Tumour Virus Res Date: 2022-05-04
Authors: Theodora M Zohoncon; Cyrille Bisseye; Florencia W Djigma; Albert T Yonli; Tegwinde R Compaore; Tani Sagna; Djeneba Ouermi; Charlemagne M R Ouédraogo; Virginio Pietra; Jean-Baptiste Nikiéma; Simon A Akpona; Jacques Simpore Journal: Mediterr J Hematol Infect Dis Date: 2013-09-02 Impact factor: 2.576
Authors: A P Ortiz; E R Unger; C Muñoz; G Panicker; G Tortolero-Luna; M Soto-Salgado; Y Otero; E Suárez; C M Pérez Journal: BMJ Open Date: 2014-02-04 Impact factor: 2.692
Authors: Felipe A Castro; Angelica Dominguez; Klaus Puschel; Vanessa Van De Wyngard; Peter J F Snijders; Silvia Franceschi; Michael Pawlita; Catterina Ferreccio Journal: BMC Infect Dis Date: 2014-07-03 Impact factor: 3.090
Authors: Ina Marie Angèle Traore; Théodora Mahoukèdè Zohoncon; Adama Dembele; Florencia W Djigma; Dorcas Obiri-Yeboah; Germain Traore; Moussa Bambara; Charlemagne Ouedraogo; Yves Traore; Jacques Simpore Journal: Biomed Res Int Date: 2016-07-20 Impact factor: 3.411